The Role of Antiepileptic Treatment in the Recurrence Rate of Seizures After First Attack: A Randomized Clinical Trial

How to Cite This Article: Assarzadegan F, Tabesh H, Hesami O, Derakhshanfar H, Beladi Moghadam N, Shoghli A, Beale A.D, Hosseini-Zijoud S.M. The Role of Antiepileptic Treatment in the Recurrence Rate of Seizures After First Attack: A Randomized Clinical Trial. Iran J Child Neurol. Spring 2015; 9(2):46-52.

Introduction
Epilepsy is one of the most common neurological disorders in the world with more than 50 million affected. The incidence rate of epilepsy in the general population is 0.2–0.4%. Researchers have shown that in developing countries, 2–4% have recurrent epileptic attacks during their lifetime (1). However, because of the side effects and cultural issues due to antiepileptic drugs, some patients refuse to use antiepileptic drugs. Considering the high incidence of convulsions and the complications of uncontrolled seizures, it is a priority to control this disorder. The mortality and morbidity rates increase in recurrent cases (1).

Abstract

Objective
Epilepsy is a serious, potentially life-shortening brain disorder that occurs in patients of all ages and races. A total of 2–4% of people have experienced seizures at least once in their lifetime. Although treatment usually begins after a seizure, it is an important question whether the first cases of seizure do need to be treated by antiepileptic drugs. In this manner, we compare the recurrence rates of epilepsy in first seizure patients treated with sodium valproic acid as an antiepileptic drug versus a placebo.

Material & Methods
In a randomized clinical trial study, 101 first seizure patients were randomly divided into two groups: one group was treated with antiepileptic drugs (sodium valproate 200mg, three times a day) and the other group was given a placebo. The recurrence rate of seizures was evaluated and compared between the groups after 6 months of follow up.

Results
Eight recurrence cases were detected. All recurrence cases came from the placebo group, with four patients suffering an additional seizure after four months and between 4-6 month follow up. A comparison of recurrence rate detected a statistically significant difference between the drug group and placebo group.

Conclusion
Our data shows that the recurrences occurred only in the placebo group with the difference between the recurrence rates in the placebo versus drug-treated was significant. Our results suggest that drug therapy for people after their first seizure attack might reduce the probability of seizure recurrence.

Keywords: Epilepsy; Recurrence rate; Seizure; Sodium valproate
There is controversy regarding treatment of first time seizure patients since they are not defined as having epilepsy after just one seizure. In order to make a decision in these cases, recurrence rates and the effectiveness of antiepileptic drugs need to be evaluated. First seizures are a terrifying experience. It has been shown that any person has a 8–10% chance of experiencing a seizure event and 3% chance of becoming epileptic (2). Most of the time, the cause of first seizure is a pathology in the central nervous system (CNS) after which the recurrence rate is 30–50%. This recurrence rate rises to 70–80% after the second unprovoked seizure making the diagnosis of epilepsy more probable (3-7).

First seizures have important differential diagnoses including syncope (breathing cessation and loss of consciousness), transient ischemic attacks (TIA), metabolic encephalopathy (hypoglycemia, electrolyte imbalances), nightmares, complex migraine, cardiac arrhythmia, and pseudoseizures. Convulsive syncope is a new topic and is defined when syncope induces seizures or death. Precise history taking is crucial for diagnosis but there is often no single diagnostic finding in patient histories. Investigations demonstrate that most patients with tonic-clonic seizures have had a previous simple or complex partial seizure (2, 8, 9). About 25–30% of first seizures are symptomatic and provoked by a CNS pathology or electrolyte imbalances or metabolic disorders (10-13). Convulsion inducing factors are fever, head trauma, excessive alcohol consumption, withdrawal syndromes of alcohol or illicit drugs, cerebral infections, ischemic attacks, intracranial hemorrhage, and drugs, such as clozapine, maprotiline, tramadol, theophylline, and baclofen, after baclofen. Seizures induced by metabolic disorders or toxicities have a lower chance of becoming epilepsy (lower than 3%) but organic disorders like cerebral abscesses increase the chance to greater than 10%. Seizures occurring after physiological stresses are not categorized as “acute symptomatic” and are instead called “triggered seizures”. Laboratory data of complete blood test and urine and cerebrospinal fluid (CSF) analysis are needed to diagnose these patients (14).

To avoid recurrent attacks, patients should be aware of inducing factors as the recurrence rate of a first seizure after two years is approximately 42% (15). The significance of two unprovoked convulsions in one day is still unclear and considering these convulsions as a single simple seizure is controversial (16). In a quantitative review, the risk of seizure recurrence near two years following first attack was 36% and 47%, in prospective and retrospective studies, respectively (15). To avoid recurrence, the recommendation is to avoid provoking activities after first seizure for three months (17). Driving restrictions after the first seizure are controversial and most neurologists believe that patients should avoid driving for 3 months.

Antiepileptics are a class of drugs that suppress attacks of epilepsy or reduce their frequency and severity. Valproic acid, often called valproate, is one such antiepileptic with a double mechanism of action: it decreases the influx of sodium and increases that of chloride by indirect Gamma-Aminobutyric Acid (GABA) mimetic effect. By these two complementary mechanisms, valproic acid increases the polarization of the cell and decreases its excitability. Its GABA-mimetic effect prevails on its effect on the voltage-dependent sodium channels. It is effective in the majority of epilepsies and is widely used (5, 10, 12).

The purpose of the current randomized clinical trial is to compare the recurrence rate of epilepsy in the first seizure patients treated with sodium valproate acid as an antiepileptic drug or placebo.

**Material & Methods**

Patients referred to the Neurology Clinic of Emam Hossein Medical and Educational Center (from 2009–2011) with a first seizure were evaluated with inclusion and exclusion criteria. In all patients, the first seizure was generalized tonic-clonic form (GTC). If the patient had a family history of seizures, history of head trauma, tumors, meningitis, and neurological disorders, they were excluded. A thorough neurologic examination, electroencephalography (EEG), and a magnetic resonance imaging (MRI) were then performed. If all of the examinations, the EEG, and the MRI were normal and the patients had not taken any specific drugs, they were then included in the project.

Patients were randomly categorized into two groups. One group (n = 50) received sodium valproate 200 mg three times a day as an antiepileptic drug and the other
University of Medical Sciences (SBMU), all patients signed a written informed consent form for this project.

**Results**

A total of 101 patients were included in this research with 50 patients receiving antiepileptic drugs (sodium valproate group) and 51 receiving a placebo (placebo group). Fifty-seven patients were male (56.9%) and 44 were female (43.1%). The mean age of patients was 34.7 ± 16.3. Patient educational status was divided into 4 levels, 10 cases (9.9%) were illiterate, 22 (21.8%) with elementary education, 45 (44.6%) with diploma, and 24 (23.7%) with masters or above. The mean duration of first seizure was 4.9 ± 4.2 minutes. There was not a significant difference in demographic characters between the two groups (p > 0.05) (Table 1).

**Table 1. Characteristics of 101 Patients in the Sodium Valproate & the Placebo Groups.**

| Data                      | Sodium Valproate (n = 50) | Placebo (n = 51) | P value |
|---------------------------|---------------------------|------------------|---------|
| Age Mean ± SD             | 33.6 ± 9.4                | 36.9 ± 7.7       | 0.19    |
| Gender                    |                           |                  |         |
| Male (n)                  | 27                        | 30               | 0.4     |
| Female (n)                | 23                        | 21               |         |
| Educational status        |                           |                  |         |
| Illiterate (n)            | 5                         | 5                |         |
| Elementary (n)            | 10                        | 12               | 0.28    |
| Diploma (n)               | 24                        | 21               |         |
| Masters or above (n)      | 11                        | 13               |         |
| Duration of first seizure (min) | Mean ± SD                 |                  |         |
|                           | 5.2 ± 4.4                 | 4.7 ± 3.9        | 0.61    |

Ninety-three patients (92.2%) did not have another seizure six months after the first seizure. Eight patients (7.8%) had recurrent seizures, of which four patients (3.9%) had seizures in the first four months. The other patients had their second seizure between 4–6 months of follow up. All of these 8 patients were in the placebo group (Figure 1). Analytical analysis shows a statistical significant difference in the recurrence rate between two groups (p = 0.04).
Antiepileptic Treatment in Recurrence Rate of Seizures

Discussion

Giving anti-epileptic drugs after the first seizure is controversial (18-23). In previous pediatric research, it was concluded that antiepileptic drugs diminish the chance of epilepsy recurrence; however, they have no role in the course of main management. Others endorse considering the likelihood of future attacks and the side effects of the drug before recommending them for first seizures (19, 20). Drugs with minimal side effects, good patient compliance, high effectiveness, and few contraindications are good choices for treatment. Phenytoin and barbiturates are unsuitable as they may cause some neurologic or psychological disorders. For focal seizures carbamazepine, clobazam (especially in pediatrics), gabapentin, carbamazepine, lamotrigine, topiramate, and valproate are recommended. The last three drugs are also used in the management of general seizures.

First seizures may lead to future complications depending on the risk factors. The chief complaint of 0.2–0.3% of emergency room (ER) patients is first seizures (24, 25). About 5% of the general population has at least experienced nonfebrile seizures in their lifetime (7, 26). Therefore, it is necessary to have a protocol for the treatment of this condition. The administration of the antiepileptic drugs after first attack is still controversial. Those supporting the use of antiepileptic drugs emphasize the importance of recurrence and prognosis of the patients. Supporting this, are researches that demonstrate that there is a 60–70% chance of recurrence after the first seizure in two years (15, 27-30). This rate is related to the primary etiology; if the cause is cerebral injury, head trauma, or other brain pathologies like tumors, then the risk of recurrence increases when compared to idiopathic seizures. Those against the use of the drugs are others who are concerned about the side effects of the drugs, especially on children.

Musicco et al. prescribed carbamazepine, phenytoin, phenobarbital, or sodium valproate to treat the case group with first seizure and delayed treatment for controls. They showed that 24% of 215 patients in the case group and 42% of 204 patients in the control group experienced a second seizure. The most important predicting risk factors were age, benzodiazepine consumption, and an abnormal EEG. A total of 68% of patients treated with antiepileptic drugs immediately after first attack were symptom free in two years. Delayed treatment resulted in a higher recurrence rate (18). Marson et al. stated (19) that these statistically significant (p<0.05) lower recurrence rate after first seizure when given

Fig 1. Seizure recurrence rates in both groups (sodium valproate 200 mg three times a day and placebo group)
antiepileptic drugs compared to a placebo group these results are similar to our conclusions (Figure 1). However, some recent articles do not support our results. Lean et al. followed patients with first seizure. They treated the case group with antiepileptic medications and non-medical treatments for others. Their results indicated that early treatment of first seizure had no effect on prognosis and did not lead to a complete cure (26). Furthermore, Temkin et al. demonstrated that there is no effective drug to use after the first unprovoked seizures (31).

Our study limitations were the number of cases, distinguishing between true seizures and seizure-like symptoms, and examining genetic disorders as an etiology of seizures. We recommend further multicentral studies using larger sample sizes, considering the exact etiology of first seizure, and a prolongation of follow up period to determine the drug of choice for treatment.

**In conclusion**, we conclude that there is a statistically significant reduction in the recurrence rate if the first time seizure patients are treated with antiepileptic medications without concern for the side effects of these drugs. Further investigations are needed on the choice of drug and the period of the treatment.

**Acknowledgment**
The authors of this investigation thank all participants that cooperated in this project; your dedication is deeply appreciated. This project was financially supported by a grant from Clinical Research Development Unit, Emam Hossein Medical and Educational Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

**Conflict of interest**
The authors of this manuscript have no invested interests in products described or used in this article. The authors have no conflicts of interest.

**Author Contribution**
Assarzadegan F.: Designer and coordinator of the project Tabesh H.: writer of the manuscript and corresponding author Hesami O., Derakhshanfar H., Beladi Moghadam N., and Shoghli A.: collecting the data and reviewing the literature

Beale A.D.: editing and revising the manuscript Hosseini-Zijoud S.M.: statistical data analyzer

**References**
1. Beghi E, Leone M, Solari A. Mortality in patients with a first unprovoked seizure. Epilepsia. 2005;46 Suppl 11:40-2. Epub 2006/01/06. doi: 10.1111/j.1528-1167.2005.00407.x. PubMed PMID: 16393178.
2. Hauser WA, Rich SS, Annegers JF, Anderson VE. Seizure recurrence after a 1st unprovoked seizure: an extended follow-up. Neurology. 1990;40(8):1163-70. Epub 1990/08/01. PubMed PMID: 2381523.
3. Shinnar S, Berg AT, O’Dell C, Newstein D, Moshe SL, Hauser WA. Predictors of multiple seizures in a cohort of children prospectively followed from the time of their first unprovoked seizure. Annals of neurology. 2000;48(2):140-7. Epub 2000/08/12. PubMed PMID: 10939563.
4. Angus-Leppan H. First seizures in adults. BMJ (Clinical research ed). 2014;348:g2470. Epub 2014/04/17. doi: 10.1136/bmj.g2470. PubMed PMID: 24736280.
5. Espinosa-Jovel CA, Sobrino-Mejia FE. [Clinical approach to the first epileptic crisis in adults]. Revista de neurologia. 2014;58(8):365-74. Epub 2014/04/12. PubMed PMID: 24723179.
6. Christensen J, Sidenius P. Epidemiology of epilepsy in adults: implementing the ILAE classification and terminology into population-based epidemiologic studies. Epilepsia. 2012;53 Suppl 2:14-7. Epub 2012/07/13. doi: 10.1111/j.1528-1167.2012.03553.x. PubMed PMID: 22765499.
7. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia. 1993;34(3):453-68. Epub 1993/05/01. PubMed PMID: 8504780.
8. Jacoby A, Snape D, Baker GA. Epilepsy and social identity: the stigma of a chronic neurological disorder. Lancet neurology. 2005;4(3):171-8. Epub 2005/02/22. doi: 10.1016/s1474-4422(05)0014-8. PubMed PMID: 15721827.
9. Addy DP. Epileptology of the first-seizure presentation. Lancet. 1998;352(9143):1857. Epub 1998/12/16. PubMed PMID: 9851409.
10. Hart YM, Sander JW, Johnson AL, Shorvon SD. National General Practice Study of Epilepsy: recurrence after a first seizure. Lancet. 1990;336(8726):1271-4. Epub 1990/11/24. PubMed PMID: 1978114.

11. Annegers JF, Hauser WA, Lee JR, Rocca WA. Incidence of acute symptomatic seizures in Rochester, Minnesota, 1935-1984. Epilepsia. 1995;36(4):327-33. Epub 1995/04/01. PubMed PMID: 7607110.

12. Beleza P. Acute symptomatic seizures: a clinically oriented review. The neurologist. 2012;18(3):109-19. Epub 2012/05/03. doi: 10.1097/NRL.0b013e318251e6c3. PubMed PMID: 22549348.

13. Lawn N, Kelly A, Dunne J, Lee J, Wesseldine A. First seizure in the older patient: clinical features and prognosis. Epilepsy research. 2013;107(1-2):109-14. Epub 2013/09/24. doi: 10.1016/j.eplepsyres.2013.08.009. PubMed PMID: 24055222.

14. Hirtz D, Ashwal S, Berg A, Bettis D, Camfield C, Camfield P, et al. Practice parameter: evaluating a first nonfebrile seizure in children: report of the quality standards subcommittee of the American Academy of Neurology, The Child Neurology Society, and The American Epilepsy Society. Neurology. 2000;55(5):616-23. Epub 2000/09/12. PubMed PMID: 10980722.

15. Berg AT, Shinnar S. The risk of seizure recurrence following a first unprovoked seizure: a quantitative review. Neurology. 1991;41(7):965-72. Epub 1991/07/01. PubMed PMID: 2067659.

16. Camfield P, Camfield C. Epilepsy can be diagnosed when the first two seizures occur on the same day. Epilepsia. 2000;41(9):1230-3. Epub 2000/09/22. PubMed PMID: 10999565.

17. ILAE Commission report. Restrictions for children with epilepsy. Commission of Pediatrics of the ILAE. International League Against Epilepsy. Epilepsia. 1997;38(9):1054-6. Epub 1998/05/14. PubMed PMID: 9579949.

18. Muscco M, Beghi E, Solari A, Viani F. Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. First Seizure Trial Group (FIRST Group). Neurology. 1997;49(4):991-8. Epub 1997/10/27. PubMed PMID: 9339678.

19. Marson A, Jacoby A, Johnson A, Kim L, Gamble C, Chadwick D. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet. 2005;365(9476):2007-13. Epub 2005/06/14. doi: 10.1016/s0140-6736(05)66694-9. PubMed PMID: 15950714.

20. Hirtz D, Berg A, Bettis D, Camfield C, Camfield P, Crumrine P, et al. Practice parameter: treatment of the child with a first unprovoked seizure: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2003;60(2):166-75. Epub 2003/01/29. PubMed PMID: 12552027.

21. Camfield C, Camfield P, Gordon K, Dooley J. Does the number of seizures before treatment influence ease of control or remission of childhood epilepsy? Not if the number is 10 or less. Neurology. 1996;46(1):41-4. Epub 1996/01/01. PubMed PMID: 8559418.

22. Berg AT, Shinnar S. Relapse following discontinuation of antiepileptic drugs: a meta-analysis. Neurology. 1994;44(4):601-8. Epub 1994/04/01. PubMed PMID: 8164811.

23. Krumholz A, Grufferman S, Orr ST, Stern BJ. Seizures and seizure care in an emergency department. Epilepsia. 1989;30(2):175-81. Epub 1989/03/01. PubMed PMID: 2924743.

24. Huff JS, Morris DL, Kothari RU, Gibbs MA. Emergency department management of patients with seizures: a multicenter study. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2001;8(6):622-8. Epub 2001/06/05. PubMed PMID: 11388937.

25. Smith AB, Van Hoving DJ, Wallis LA. Emergency centre investigation of first-onset seizures in adults in the Western Cape, South Africa. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 2013;103(10):723-7. Epub 2013/10/02. doi: 10.7196/samj.6821. PubMed PMID: 2407622.

26. Leone MA, Solari A, Beghi E. Treatment of the first tonic-clonic seizure does not affect long-term remission of epilepsy. Neurology. 2006;67(12):2227-9. Epub 2006/12/28. doi: 10.1212/01.wnl.0000249309.80510.63. PubMed PMID: 17190950.

27. Schreiner A, Pohlmann-Eden B. Value of the early electroencephalogram after a first unprovoked seizure.
Clinical EEG (electroencephalography). 2003;34(3):140-4. Epub 2003/10/03. PubMed PMID: 14521275.

28. Maillard L, Jonas J, Boyer R, Frismand S, Mathey G, Vignal JP, et al. One-year outcome after a first clinically possible epileptic seizure: predictive value of clinical classification and early EEG. Neurophysiologie clinique = Clinical neurophysiology. 2012;42(6):355-62. Epub 2012/11/28. doi: 10.1016/j.neucli.2012.07.002. PubMed PMID: 23181965.

29. Askamp J, van Putten MJ. Diagnostic decision-making after a first and recurrent seizure in adults. Seizure : the journal of the British Epilepsy Association. 2013;22(7):507-11. Epub 2013/04/30. doi: 10.1016/j.seizure.2013.03.012. PubMed PMID: 23623152.

30. Su L, Di Q, Yu N, Zhang Y. Predictors for relapse after antiepileptic drug withdrawal in seizure-free patients with epilepsy. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2013;20(6):790-4. Epub 2013/05/02. doi: 10.1016/j.jocn.2012.07.010. PubMed PMID: 23632288.

31. Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia. 2001;42(4):515-24. Epub 2001/07/07. PubMed PMID: 11440347.